

ABSTRACT**NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES**

This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-
5 neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.

Figure 8